Participants with ARID1A− and ARID1A+, had a low stage of cancer according to FIGO (International Federation of Gynecology and Obstetrics) in 66.1% and 87.0% of cases (p = 0.26), with the corresponding figures being 53.1% and 63.6% (p = 0.002) using the TNM classification. This evidence concerns the gene ARID1A and cancer.